D
PTC Therapeutics, Inc.
PTCT
$41.40
-$1.43-3.33%
D
Sell
4/12/2024Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D- from E+ on 4/12/2024 due to an increase in the solvency index, total return index and volatility index.
PTC Therapeutics, Inc. (PTCT) was upgraded to D- from E+ on 4/12/2024 due to an increase in the solvency index, total return index and volatility index.
E
Sell
3/28/2024Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D- on 3/28/2024 due to a decline in the solvency index and volatility index.
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D- on 3/28/2024 due to a decline in the solvency index and volatility index.
D
Sell
3/6/2024Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D- from E+ on 3/6/2024 due to an increase in the volatility index, solvency index and total return index. The quick ratio increased from 0.94 to 1.72, and debt to equity declined from -2.01 to -2.58.
PTC Therapeutics, Inc. (PTCT) was upgraded to D- from E+ on 3/6/2024 due to an increase in the volatility index, solvency index and total return index. The quick ratio increased from 0.94 to 1.72, and debt to equity declined from -2.01 to -2.58.
E
Sell
2/29/2024Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D- on 2/29/2024 due to a decline in the volatility index.
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D- on 2/29/2024 due to a decline in the volatility index.
D
Sell
2/12/2024Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D- from E+ on 2/12/2024 due to an increase in the volatility index and total return index.
PTC Therapeutics, Inc. (PTCT) was upgraded to D- from E+ on 2/12/2024 due to an increase in the volatility index and total return index.
E
Sell
1/24/2024Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D- on 1/24/2024 due to a decline in the volatility index.
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D- on 1/24/2024 due to a decline in the volatility index.
D
Sell
1/4/2024Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index.
PTC Therapeutics, Inc. (PTCT) was upgraded to D- from E+ on 1/4/2024 due to an increase in the volatility index.
E
Sell
12/15/2023Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D- on 12/15/2023 due to a large decline in the total return index, solvency index and volatility index. The quick ratio declined from 1.1 to 0.94, and debt to equity increased from -2.33 to -2.01.
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D- on 12/15/2023 due to a large decline in the total return index, solvency index and volatility index. The quick ratio declined from 1.1 to 0.94, and debt to equity increased from -2.33 to -2.01.
D
Sell
3/14/2023Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D- from D on 03/14/2023.
PTC Therapeutics, Inc. (PTCT) was downgraded to D- from D on 03/14/2023.
D
Sell
2/23/2023Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 2/23/2023 due to a noticeable decline in the growth index and solvency index. Operating cash flow declined 336.23% from -$38.05M to -$165.96M, EBIT declined 145.52% from -$70.62M to -$173.39M, and earnings per share declined from -$1.53 to -$2.3567.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 2/23/2023 due to a noticeable decline in the growth index and solvency index. Operating cash flow declined 336.23% from -$38.05M to -$165.96M, EBIT declined 145.52% from -$70.62M to -$173.39M, and earnings per share declined from -$1.53 to -$2.3567.
D
Sell
2/9/2023Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D- on 2/9/2023 due to an increase in the total return index.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D- on 2/9/2023 due to an increase in the total return index.
D
Sell
2/8/2023Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D- from D+ on 2/8/2023 due to a decline in the total return index and valuation index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D- from D+ on 2/8/2023 due to a decline in the total return index and valuation index.
D
Sell
1/11/2023Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 1/11/2023 due to an increase in the volatility index.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 1/11/2023 due to an increase in the volatility index.
D
Sell
12/27/2022Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 12/27/2022 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from -2.43 to -1.3, and the quick ratio declined from 1.13 to 0.98.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 12/27/2022 due to a decline in the volatility index, total return index and solvency index. Debt to equity increased from -2.43 to -1.3, and the quick ratio declined from 1.13 to 0.98.
D
Sell
9/13/2022Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 9/13/2022 due to a major increase in the total return index and volatility index.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 9/13/2022 due to a major increase in the total return index and volatility index.
D
Sell
5/31/2022Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index.
PTC Therapeutics, Inc. (PTCT) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index.
D
Sell
5/13/2022Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D- from D on 5/13/2022 due to a large decline in the solvency index, volatility index and total return index. The quick ratio declined from 1.74 to 1.53.
PTC Therapeutics, Inc. (PTCT) was downgraded to D- from D on 5/13/2022 due to a large decline in the solvency index, volatility index and total return index. The quick ratio declined from 1.74 to 1.53.
D
Sell
5/4/2022Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D from E+ on 05/04/2022.
PTC Therapeutics, Inc. (PTCT) was upgraded to D from E+ on 05/04/2022.
E
Sell
5/1/2022Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index and total return index.
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D- on 5/1/2022 due to a decline in the volatility index and total return index.
D
Sell
4/20/2022Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the growth index, valuation index and solvency index. Debt to equity increased from 4.2 to 307.17, EBIT declined 66.97% from -$75.15M to -$125.47M, and operating cash flow declined 34.48% from -$51.19M to -$68.84M.
PTC Therapeutics, Inc. (PTCT) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the growth index, valuation index and solvency index. Debt to equity increased from 4.2 to 307.17, EBIT declined 66.97% from -$75.15M to -$125.47M, and operating cash flow declined 34.48% from -$51.19M to -$68.84M.
D
Sell
11/9/2021Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D from E+ on 11/09/2021.
PTC Therapeutics, Inc. (PTCT) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D on 11/8/2021 due to a major decline in the total return index, volatility index and solvency index. Debt to equity increased from 2.24 to 4.2, and the quick ratio declined from 3.53 to 2.07.
PTC Therapeutics, Inc. (PTCT) was downgraded to E+ from D on 11/8/2021 due to a major decline in the total return index, volatility index and solvency index. Debt to equity increased from 2.24 to 4.2, and the quick ratio declined from 3.53 to 2.07.
D
Sell
4/12/2021Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 4/12/2021 due to a decline in the total return index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 4/12/2021 due to a decline in the total return index.
D
Sell
3/8/2021Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 3/8/2021 due to an increase in the solvency index and volatility index. Debt to equity declined from 1.91 to 0.66.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 3/8/2021 due to an increase in the solvency index and volatility index. Debt to equity declined from 1.91 to 0.66.
D
Sell
1/28/2021Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 1/28/2021 due to a decline in the volatility index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 1/28/2021 due to a decline in the volatility index.
D
Sell
12/4/2020Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 12/4/2020 due to an increase in the growth index and volatility index. Operating cash flow increased 135.64% from -$74.81M to $26.66M, EBIT increased 72.35% from -$168.98M to -$46.73M, and earnings per share increased from -$2.7847 to -$1.0303.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 12/4/2020 due to an increase in the growth index and volatility index. Operating cash flow increased 135.64% from -$74.81M to $26.66M, EBIT increased 72.35% from -$168.98M to -$46.73M, and earnings per share increased from -$2.7847 to -$1.0303.
D
Sell
5/1/2020Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 5/1/2020 due to a noticeable decline in the solvency index, efficiency index and volatility index. Net income declined 45.07% from -$77.68M to -$112.69M, debt to equity increased from 0.54 to 0.6, and total capital declined 6.59% from $922.36M to $861.54M.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 5/1/2020 due to a noticeable decline in the solvency index, efficiency index and volatility index. Net income declined 45.07% from -$77.68M to -$112.69M, debt to equity increased from 0.54 to 0.6, and total capital declined 6.59% from $922.36M to $861.54M.
D
Sell
2/12/2020Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D+ from C- on 2/12/2020 due to a noticeable decline in the total return index, volatility index and valuation index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D+ from C- on 2/12/2020 due to a noticeable decline in the total return index, volatility index and valuation index.
C
Hold
1/28/2020Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to C- from D+ on 1/28/2020 due to a substantial increase in the total return index.
PTC Therapeutics, Inc. (PTCT) was upgraded to C- from D+ on 1/28/2020 due to a substantial increase in the total return index.
D
Sell
1/6/2020Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 1/6/2020 due to an increase in the volatility index, efficiency index and solvency index. The quick ratio increased from 2.53 to 4.19, and total capital increased 51.29% from $654.93M to $990.86M.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 1/6/2020 due to an increase in the volatility index, efficiency index and solvency index. The quick ratio increased from 2.53 to 4.19, and total capital increased 51.29% from $654.93M to $990.86M.
D
Sell
10/3/2019Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 10/3/2019 due to a significant decline in the total return index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 10/3/2019 due to a significant decline in the total return index.
D
Sell
8/7/2019Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 8/7/2019 due to a significant increase in the total return index, volatility index and efficiency index. Net income increased 42.05% from -$72.11M to -$41.79M.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 8/7/2019 due to a significant increase in the total return index, volatility index and efficiency index. Net income increased 42.05% from -$72.11M to -$41.79M.
D
Sell
3/5/2019Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 3/5/2019 due to a decline in the valuation index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 3/5/2019 due to a decline in the valuation index.
D
Sell
1/25/2019Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 1/25/2019 due to an increase in the valuation index.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 1/25/2019 due to an increase in the valuation index.
D
Sell
1/9/2019Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 1/9/2019 due to a decline in the valuation index and volatility index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 1/9/2019 due to a decline in the valuation index and volatility index.
D
Sell
12/21/2018Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 12/21/2018 due to an increase in the valuation index.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 12/21/2018 due to an increase in the valuation index.
D
Sell
12/6/2018Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 12/6/2018 due to a decline in the valuation index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 12/6/2018 due to a decline in the valuation index.
D
Sell
11/19/2018Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 11/19/2018 due to an increase in the efficiency index, volatility index and solvency index. Debt to equity declined from 0.56 to 0.39, and total capital increased 29.01% from $416.27M to $537.02M.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 11/19/2018 due to an increase in the efficiency index, volatility index and solvency index. Debt to equity declined from 0.56 to 0.39, and total capital increased 29.01% from $416.27M to $537.02M.
D
Sell
8/11/2017Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D from D- on 8/11/2017 due to a substantial increase in the total return index, growth index and volatility index. Operating cash flow increased 146.09% from -$28.9M to $13.32M, total revenue increased 80.67% from $26.55M to $47.96M, and EBIT increased 52.58% from -$26.36M to -$12.5M.
PTC Therapeutics, Inc. (PTCT) was upgraded to D from D- on 8/11/2017 due to a substantial increase in the total return index, growth index and volatility index. Operating cash flow increased 146.09% from -$28.9M to $13.32M, total revenue increased 80.67% from $26.55M to $47.96M, and EBIT increased 52.58% from -$26.36M to -$12.5M.
D
Sell
4/14/2016Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D- from D on 4/14/2016 due to a significant decline in the volatility index and total return index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D- from D on 4/14/2016 due to a significant decline in the volatility index and total return index.
D
Sell
3/4/2016Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 3/4/2016 due to a noticeable decline in the volatility index, solvency index and efficiency index. The quick ratio declined from 11.97 to 7.71, debt to equity increased from 0.35 to 0.42, and total capital declined 11.52% from $362.35M to $320.61M.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 3/4/2016 due to a noticeable decline in the volatility index, solvency index and efficiency index. The quick ratio declined from 11.97 to 7.71, debt to equity increased from 0.35 to 0.42, and total capital declined 11.52% from $362.35M to $320.61M.
D
Sell
1/22/2016Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 1/22/2016 due to a substantial increase in the volatility index and valuation index.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 1/22/2016 due to a substantial increase in the volatility index and valuation index.
D
Sell
1/7/2016Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 1/7/2016 due to a decline in the volatility index and valuation index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from D+ on 1/7/2016 due to a decline in the volatility index and valuation index.
D
Sell
12/10/2015Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 12/10/2015 due to an increase in the valuation index and efficiency index. Total capital increased 45.77% from $248.58M to $362.35M, and net income increased 12.67% from -$38.36M to -$43.22M.
PTC Therapeutics, Inc. (PTCT) was upgraded to D+ from D on 12/10/2015 due to an increase in the valuation index and efficiency index. Total capital increased 45.77% from $248.58M to $362.35M, and net income increased 12.67% from -$38.36M to -$43.22M.
D
Sell
5/7/2015Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from C- on 5/7/2015 due to a substantial decline in the efficiency index, total return index and valuation index. Total capital declined 8.43% from $298.47M to $273.32M.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from C- on 5/7/2015 due to a substantial decline in the efficiency index, total return index and valuation index. Total capital declined 8.43% from $298.47M to $273.32M.
C
Hold
11/7/2014Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to C- from D+ on 11/7/2014 due to an increase in the growth index, efficiency index and valuation index. EBIT increased 8.8% from -$25.37M to -$27.6M, net income increased 8.68% from -$25.1M to -$27.28M, and earnings per share increased from -$0.8559 to -$0.9295.
PTC Therapeutics, Inc. (PTCT) was upgraded to C- from D+ on 11/7/2014 due to an increase in the growth index, efficiency index and valuation index. EBIT increased 8.8% from -$25.37M to -$27.6M, net income increased 8.68% from -$25.1M to -$27.28M, and earnings per share increased from -$0.8559 to -$0.9295.
D
Sell
11/3/2014Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D+ from C- on 11/3/2014 due to a decline in the valuation index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D+ from C- on 11/3/2014 due to a decline in the valuation index.
C
Hold
9/15/2014Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to C- from D on 9/15/2014 due to a large increase in the volatility index and total return index.
PTC Therapeutics, Inc. (PTCT) was upgraded to C- from D on 9/15/2014 due to a large increase in the volatility index and total return index.
D
Sell
9/12/2014Downgrade
PTC Therapeutics, Inc. (PTCT) was downgraded to D from C- on 9/12/2014 due to a decline in the valuation index.
PTC Therapeutics, Inc. (PTCT) was downgraded to D from C- on 9/12/2014 due to a decline in the valuation index.
C
Hold
9/8/2014Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to C- from D on 9/8/2014 due to a major increase in the efficiency index, total return index and volatility index. Net income increased 78.07% from -$14.1M to -$25.1M.
PTC Therapeutics, Inc. (PTCT) was upgraded to C- from D on 9/8/2014 due to a major increase in the efficiency index, total return index and volatility index. Net income increased 78.07% from -$14.1M to -$25.1M.
D
Sell
7/1/2014Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D from D- on 7/1/2014 due to an increase in the valuation index, volatility index and solvency index. The quick ratio increased from 10.92 to 26.78.
PTC Therapeutics, Inc. (PTCT) was upgraded to D from D- on 7/1/2014 due to an increase in the valuation index, volatility index and solvency index. The quick ratio increased from 10.92 to 26.78.
D
Sell
3/3/2014Upgraded
PTC Therapeutics, Inc. (PTCT) was upgraded to D- from E+ on 3/3/2014 due to a major increase in efficiency, stability and total return.
PTC Therapeutics, Inc. (PTCT) was upgraded to D- from E+ on 3/3/2014 due to a major increase in efficiency, stability and total return.
NASDAQ
04/08/2025 1:46PM Eastern
Quotes delayed
